Stephen H Bryant
Overview
Explore the profile of Stephen H Bryant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
16974
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Madej T, Marchler-Bauer A, Lanczycki C, Zhang D, Bryant S
Methods Mol Biol
. 2020 Feb;
2112:175-186.
PMID: 32006286
The VAST+ algorithm is an efficient, simple, and elegant solution to the problem of comparing the atomic structures of biological assemblies. Given two protein assemblies, it takes as input all...
2.
Wang J, Youkharibache P, Zhang D, Lanczycki C, Geer R, Madej T, et al.
Bioinformatics
. 2019 Jun;
36(1):131-135.
PMID: 31218344
Motivation: Build a web-based 3D molecular structure viewer focusing on interactive structural analysis. Results: iCn3D (I-see-in-3D) can simultaneously show 3D structure, 2D molecular contacts and 1D protein and nucleotide sequences...
3.
Kim S, Shoemaker B, Bolton E, Bryant S
Methods Mol Biol
. 2018 Oct;
1825:63-91.
PMID: 30334203
PubChem ( https://pubchem.ncbi.nlm.nih.gov ) is a key chemical information resource, developed and maintained by the US National Institutes of Health. The present chapter describes how to find potential multitarget ligands...
4.
Hao M, Bryant S, Wang Y
J Cheminform
. 2018 Oct;
10(1):50.
PMID: 30311095
Background: Fast and accurate identification of potential drug candidates against therapeutic targets (i.e., drug-target interactions, DTIs) is a fundamental step in the early drug discovery process. However, experimental determination of...
5.
Butkiewicz M, Wang Y, Bryant S, Lowe Jr E, Weaver D, Meiler J
Chem Inform
. 2018 May;
3(1).
PMID: 29795804
Availability of high-throughput screening (HTS) data in the public domain offers great potential to foster development of ligand-based computer-aided drug discovery (LB-CADD) methods crucial for drug discovery efforts in academia...
6.
Hao M, Bryant S, Wang Y
Brief Bioinform
. 2018 Feb;
20(4):1465-1474.
PMID: 29420684
While novel technologies such as high-throughput screening have advanced together with significant investment by pharmaceutical companies during the past decades, the success rate for drug development has not yet been...
7.
Bryant S, Beckenbach A, Cobbs G
Evolution
. 2017 Jun;
36(1):27-34.
PMID: 28581105
No abstract available.
8.
Cheng T, Hao M, Takeda T, Bryant S, Wang Y
AAPS J
. 2017 Jun;
19(5):1264-1275.
PMID: 28577120
The prediction of drug-target interactions (DTIs) is of extraordinary significance to modern drug discovery in terms of suggesting new drug candidates and repositioning old drugs. Despite technological advances, large-scale experimental...
9.
Wang Y, Cheng T, Bryant S
SLAS Discov
. 2017 Mar;
22(6):655-666.
PMID: 28346087
High-throughput screening (HTS) is now routinely conducted for drug discovery by both pharmaceutical companies and screening centers at academic institutions and universities. Rapid advance in assay development, robot automation, and...
10.
Takeda T, Hao M, Cheng T, Bryant S, Wang Y
J Cheminform
. 2017 Mar;
9:16.
PMID: 28316654
Drug-drug interactions (DDIs) may lead to adverse effects and potentially result in drug withdrawal from the market. Predicting DDIs during drug development would help reduce development costs and time by...